MedPath

To study the effect of KANTAKARYAVALEHYA (a drug used in treating Asthma, Bronchitis, Cough) on ECP (a specific protein of Eosinophils involved in Asthma) Levels in Childhood asthma

Not Applicable
Completed
Conditions
Health Condition 1: null- CHILDHOOD ASTHMA
Registration Number
CTRI/2016/08/007211
Lead Sponsor
RGUHS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1.Patients in the age group of 5 to 15 years.

2.Atopics

3.Intermittent, Mild Persistent and Moderate Persistent Asthma.

Exclusion Criteria

1.Patients with Cardiovascular, Renal and other systemic disorders.

2.Patients with other chronic and infective disorders of respiratory system.

3.Primary Complex.

4.Foreign body aspiration.

5.Acute Severe Asthma.

6.Severe Persistent Asthma

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The efficacy of Kantakaryavalehya is already proved in the previous study done by the Principal Investigator. This study intends to look into the effect of the same drug on Asthma specific marker - ECP levels in cases of Childhood asthmaTimepoint: The efficacy of Kantakaryavalehya is already proved in the previous study done by the Principal Investigator. This study intends to look into the effect of the same drug on Asthma specific marker - ECP levels in cases of Childhood asthma
Secondary Outcome Measures
NameTimeMethod
1. Being a cost effective treatment modality <br/ ><br>2. Treatment modality with Nil or very minimal side effects <br/ ><br>3. Other add on benefits like increase in appetiteTimepoint: 2 YEARS
© Copyright 2025. All Rights Reserved by MedPath